JP2025516005A5 - - Google Patents

Info

Publication number
JP2025516005A5
JP2025516005A5 JP2024563159A JP2024563159A JP2025516005A5 JP 2025516005 A5 JP2025516005 A5 JP 2025516005A5 JP 2024563159 A JP2024563159 A JP 2024563159A JP 2024563159 A JP2024563159 A JP 2024563159A JP 2025516005 A5 JP2025516005 A5 JP 2025516005A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
alkyl
isomer
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563159A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516005A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/019879 external-priority patent/WO2023211990A1/en
Publication of JP2025516005A publication Critical patent/JP2025516005A/ja
Publication of JP2025516005A5 publication Critical patent/JP2025516005A5/ja
Pending legal-status Critical Current

Links

JP2024563159A 2022-04-25 2023-04-25 疼痛の処置のためのnav1.8の二環式複素環アミド阻害剤 Pending JP2025516005A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN202211024240 2022-04-25
IN202211024240 2022-04-25
IN202311013223 2023-02-27
IN202311013223 2023-02-27
PCT/US2023/019879 WO2023211990A1 (en) 2022-04-25 2023-04-25 Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain

Publications (2)

Publication Number Publication Date
JP2025516005A JP2025516005A (ja) 2025-05-23
JP2025516005A5 true JP2025516005A5 (2) 2026-03-17

Family

ID=86469337

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563159A Pending JP2025516005A (ja) 2022-04-25 2023-04-25 疼痛の処置のためのnav1.8の二環式複素環アミド阻害剤

Country Status (16)

Country Link
EP (1) EP4514789A1 (2)
JP (1) JP2025516005A (2)
KR (1) KR20250006217A (2)
CN (1) CN119585247A (2)
AU (1) AU2023263309A1 (2)
CA (1) CA3256486A1 (2)
CL (1) CL2024003258A1 (2)
CO (1) CO2024015763A2 (2)
CR (1) CR20240512A (2)
DO (1) DOP2024000215A (2)
GE (1) GEAP202516637A (2)
IL (1) IL316433A (2)
JO (1) JOP20240238A1 (2)
MX (1) MX2024013065A (2)
PE (1) PE20251183A1 (2)
WO (1) WO2023211990A1 (2)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4570788A1 (en) 2022-08-12 2025-06-18 Guangzhou Fermion Technology Co., Ltd. Compound as voltage-gated sodium channel inhibitor
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
WO2025228420A1 (zh) * 2024-04-30 2025-11-06 江苏恒瑞医药股份有限公司 芳香环类化合物、其制备方法及其在医药上的应用
WO2026001999A1 (zh) * 2024-06-25 2026-01-02 江苏恒瑞医药股份有限公司 芳香环类化合物、其制备方法及其在医药上的应用
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE3211934A1 (de) * 1982-03-31 1983-10-13 Hoechst Ag, 6230 Frankfurt Salicylsaeurederivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
WO1998027980A2 (en) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2006503094A (ja) * 2002-10-16 2006-01-26 スミスクライン ビーチャム コーポレーション 化合物
ES2377988T3 (es) * 2005-11-14 2012-04-03 Vertex Pharmaceuticals, Inc. Quinazolinas útiles como moduladores de canales iónicos controlados por voltaje
WO2008135830A1 (en) 2007-05-03 2008-11-13 Pfizer Limited N- [6-amino-s- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain
CA2850925C (en) 2011-10-26 2017-01-10 Pfizer Limited (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
JP6002785B2 (ja) 2012-02-03 2016-10-05 ファイザー・インク ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体
RS56015B1 (sr) 2013-01-31 2017-09-29 Vertex Pharma Piridon amidi kao modulatori natrijumovih kanala
CA2898653C (en) 2013-01-31 2021-09-28 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
RU2683788C2 (ru) 2013-01-31 2019-04-02 Вертекс Фармасьютикалз Инкорпорейтед Амиды хинолина и хиназолина, полезные в качестве модуляторов натриевых каналов
UA119147C2 (uk) 2013-07-19 2019-05-10 Вертекс Фармасьютікалз Інкорпорейтед Сульфонаміди як модулятори натрієвих каналів
CA2931550C (en) 2013-12-13 2023-09-26 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
TWI735416B (zh) * 2014-10-06 2021-08-11 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
EP3625214B1 (en) 2017-05-16 2022-07-06 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
AU2018300150A1 (en) 2017-07-11 2020-01-30 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US11529337B2 (en) 2018-02-12 2022-12-20 Vertex Pharmaceuticals Incorporated Method of treating pain
CA3105657A1 (en) 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting nav1.8
AU2019302534B2 (en) 2018-07-09 2024-10-03 Lieber Institute, Inc. Pyridazine compounds for inhibiting NaV1.8
JP7288051B2 (ja) 2018-11-02 2023-06-06 メルク・シャープ・アンド・ドーム・エルエルシー Nav1.8阻害薬としての2-アミノ-N-ヘテロアリール-ニコチンアミド類
US12344595B2 (en) 2018-11-02 2025-07-01 Merck Sharp & Dohme Llc 2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
MX2021015605A (es) 2019-06-27 2022-02-16 Glaxosmithkline Ip Dev Ltd Compuestos 2,3-dihidroquinazolin como inhibidores nav1.8.
WO2021032074A1 (zh) 2019-08-19 2021-02-25 江苏恒瑞医药股份有限公司 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用
BR112022010924A2 (pt) 2019-12-06 2022-09-06 Vertex Pharma Tetra-hidrofuranos substituídos como moduladores de canais de sódio
US12516046B2 (en) 2020-06-17 2026-01-06 Merck Sharp & Dohme Llc 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors
US11802122B2 (en) 2020-06-17 2023-10-31 Merck Sharp & Dohme Llc 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors
CN115697327A (zh) 2020-06-17 2023-02-03 默沙东有限责任公司 作为nav1.8抑制剂的5-氧代-吡咯烷-3-甲酰胺
CN114591293A (zh) * 2020-12-07 2022-06-07 成都康弘药业集团股份有限公司 作为Nav1.8抑制剂的并环化合物及其用途

Similar Documents

Publication Publication Date Title
JP2025516005A5 (2)
JP6134046B1 (ja) 医療で使用されるインドール誘導体
TWI436986B (zh) 新穎之2環性雜環化合物
TWI487701B (zh) 作為蛋白質激酶抑制劑之化合物及組合物
TWI500616B (zh) 新穎之雙環吡啶酮
US20140343084A1 (en) Imidazopyrrolidinone compounds
JP2013542256A5 (2)
KR20170081204A (ko) 제약 화합물
JP2005536475A5 (2)
WO2016071283A1 (en) Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase
JP2015503507A5 (2)
RU2009147708A (ru) Производные оксадиазола и их применение в качестве потенцирующих средств метаботропных глутаматных рецепторов-842
SI3009431T1 (en) 2- (2,4,5-substituted-anilino) pyrimidine derivatives, as EGFR modulators useful for the treatment of cancer
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
JP2011509309A5 (2)
CN101678107A (zh) 用于治疗杜兴型肌营养不良的药物组合物
JP2016528301A5 (2)
CN1561393A (zh) 用于治疗青光眼的糖原合成酶激酶-3(gsk-3)的抑制剂
JP2006501201A5 (2)
CN112654349A (zh) PIKfyve抑制剂
EA037587B1 (ru) Способ получения противогрибковых соединений
MA30704B1 (fr) Compositions therapeutiques
TW201636339A (zh) 作爲磷脂醯肌醇3-激酶δ抑制劑的取代嘧啶類化合物及其應用
CN109069461A (zh) 与髓源性抑制细胞相关的病症的治疗方法
US20240390399A1 (en) Materials and methods for suppressing and/or treating bone related diseases and symptoms